Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Fiverr International Ltd (FVRR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Fiverr International Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Fiverr International Ltd trades at $11.05 (market cap $396.90M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 100.5× Fiverr International Ltd's market cap. Which is the better fit depends on your goals.
| ALNY | FVRR | |
|---|---|---|
Market Cap | $39.89B | $396.90M |
Sector | Health | Industrials |
52-Week High | $491.22 | $27.25 |
52-Week Low | $278.09 | $9.62 |
Enterprise Value | $38.15B | $127.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Fiverr International (FVRR) trades at $11.04, up 1.1% on the day, with a bullish technical signal and strong valuation metrics including a P/E of 14.34 and P/S of 0.95. Revenue grew to $430.91M in 2025, with net income reaching $20.98M, though Q1 2026 EPS missed expectations. The company maintains a robust gross margin of 81.86% and has beaten earnings estimates in two of the last three quarters, with Q2 2026 results due July 29, 2026.
The outlook is mixed: low valuations and improving profitability support upside, but declining active buyers and a pending legal investigation pose risks. Analyst consensus is cautious with 41% buy ratings. Near-term performance hinges on Q2 earnings demonstrating growth stabilization amid competitive pressures in the gig economy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →
